Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Hematologic neoplasms

Solitary plasmacytoma

Reviewers: Nikhil Sangle, M.D., University of Utah and ARUP Laboratories (see Reviewers page)
Revised: 15 August 2013, last major update March 2011
Copyright: (c) 2003-2013, PathologyOutlines.com, Inc.

Clinical features

● Infrequent (3-5%) variant of myeloma
● Single bone lesion with monoclonal plasma cell infiltrate
● No other lytic bone lesions
● No plasma cell infiltrates in random bone marrow biopsies
● Most commonly involves bones with active hematopoiesis vertebrae, ribs, skull, pelvis, femur
● Rarely involves lymph nodes or peripheral blood
● Causes local bony destruction, pathologic bone fractures at same sites as myeloma
● No anemia, hypercalcemia or renal failure
● Usually progresses to myeloma, but may take 10-20 years


● Expansion of a single clone of immunoglobulin secreting plasma cells; increase in serum levels of single homogeneous immunoglobulin (monoclonal spike on serum electrophoresis)

Radiology images

Pelvis xray - contributed by Dr. Mark R. Wick

Skull xray - contributed by Dr. Mark R. Wick

Case reports

● 36 year old man with tumor containing anaplastic cytology (Arch Pathol Lab Med 2004;128:237)

Micro description

● Monoclonal plasma cell infiltrate

Micro images

Various images

With amyloid congo red stain - contributed by Dr. Mark R. Wick

End of Bone > Hematologic neoplasms > Solitary plasmacytoma

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).